STOCK TITAN

Point72 group discloses 533,965 shares in Tenax Therapeutics (NASDAQ: TENX)

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Tenax Therapeutics filing amended Schedule 13G/A reporting that Point72-affiliated persons beneficially own 533,965 shares of common stock, representing 3.1% of the class as of the close of business on March 31, 2026. The holdings are reported for Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen.

The filing states the shares are held by an investment fund managed by Point72 Asset Management; the reporting persons assert shared voting and dispositive power over the 533,965 shares. Signature block shows authorization by Jason M. Colombo dated 05/15/2026.

Positive

  • None.

Negative

  • None.

Insights

Point72 reports a passive >3% stake in Tenax as of March 31, 2026.

Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen are disclosed as reporting persons with shared voting and dispositive power over 533,965 shares (3.1%). The position is held through an investment fund managed by Point72 Asset Management.

Proceeds/cash-flow treatment are not described in the excerpt; future filings would show any change in position. The filing is an ownership disclosure under Schedule 13G/A rather than an active transaction notice.

Shares beneficially owned 533,965 shares as of March 31, 2026
Percent of class 3.1% as of March 31, 2026
CUSIP 88032L605 Tenax common stock identifier
Signature date 05/15/2026 authorization by Jason M. Colombo
investment management agreement regulatory
"Point72 Asset Management maintains investment and voting power"
An investment management agreement is a written contract that hires a professional to make buying, selling and strategy decisions for an investment account or fund, and sets out their duties, fees, risk limits, performance measures and reporting requirements. It matters to investors because the agreement determines who controls the money, how much the service costs, what risks are allowed, and how success or failure is measured—think of it as the service contract that defines expectations and remedies for a hired portfolio manager.
beneficially owned financial
"Amount beneficially owned: The information required by Item 4(a)"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared dispositive power regulatory
"Shared Dispositive Power 533,965.00"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stake does Point72 report in TENX?

Point72-affiliated reporting persons disclose beneficial ownership of 533,965 shares, equal to 3.1% of Tenax Therapeutics' common stock as of March 31, 2026. The shares are held by an investment fund managed by Point72 Asset Management.

Who are the reporting persons for the TENX 13G/A amendment?

The statement is filed by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen. Point72 Capital Advisors is the general partner and Mr. Cohen controls both entities, per the filing's disclosures.

What voting and dispositive powers are reported?

The filing shows 0 sole voting power and 533,965 shared voting power; likewise 0 sole dispositive power and 533,965 shared dispositive power. These figures are reported as of March 31, 2026 on the cover page.

Does the filing state the shares are directly owned by the reporting persons?

No. The filing states Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own no shares directly; the disclosed interest reflects securities held by an investment fund managed by Point72 Asset Management.

When was the 13G/A amendment signed and filed?

The authorization signature block is dated 05/15/2026 and is signed by Jason M. Colombo as an authorized person for each reporting entity, per the excerpt provided.





88032L605

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:05/15/2026
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:05/15/2026
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:05/15/2026